It is very important to capitalise on innovative developments and implement the latest in-vitro and in-silico models to address the continual challenge of in-vitro and in-vivo extrapolation. In this Pharma IQ interview we are joined by Jorge I. González Borroto, senior toxicologist for pharmacology and safety at Ferrer International.
To continue reading this story Click Here
RECOMMENDED
MSD announces Phase III data on investigational treatment to lower LDL Cholesterol (LDL-C)
2025-11-17
AI for Pharma & Healthcare 2025
2025-06-18
Upcoming Events
Pharma Contract Manufacturing
23 - 25 March 2026
Mercure Hotel MOA Berlin, Germany
Register Now |
View Agenda |
Learn More